Marshall Wace
RANI icon

Marshall Wace’s Rani Therapeutics RANI Stock Holding History

Marshall Wace’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-21,247
Closed -$80.7K – 2881
2024
Q2 		$80.7K Buy
+21,247
New +$110K ﹤0.01% 2409

Other funds holding RANI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $23.1B AUM 21.31% 1-Year Est. Return

Marshall Wace's RANI Position: Q3 2024 in Review

Marshall Wace sold out of Rani Therapeutics (RANI) in Q3 2024, closing a stake of 21,247 shares — an estimated $80.7K sold.

Marshall Wace first reported a position in RANI in Q2 2024 and held it in 1 quarter. The position peaked at $80.7K in Q2 2024. 31 funds tracked by Wall St. Rank hold RANI as of Q3 2024.

  • Marshall Wace reported no remaining Rani Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Marshall Wace sold 21,247 Rani Therapeutics shares in Q3 2024, an estimated $80.7K.
  • Marshall Wace first reported a position in Rani Therapeutics in Q2 2024 and held it in 1 quarter.
  • Marshall Wace's Rani Therapeutics position peaked at $80.7K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2024.

Based on Marshall Wace's 13F filing for Q3 2024, filed 14 Nov 2024.